Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 4/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.58 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.58 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22265220 | 0.94 | APP (0.60) | BCHELMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL17609152 | 0.90 | BCHE (0.58) | BCHECYP1A2CYP2C19GAAMAPT | |
| SCHEMBL17609128 | 0.87 | ALOX5 (0.54) | BCHEPTGS1PTGS2MAOBL3MBTL1 | |
| Sulfurous Acid SCHEMBL28555351 | 0.87 | LMNA (0.51) | BCHELMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL28724147 | 0.85 | LMNA (0.60) | BCHELMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL2772725 | 0.84 | FFAR1 (0.61) | BCHELMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL10609652 | 0.83 | LMNA (0.75) | BCHELMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL27367676 | 0.83 | LMNA (0.82) | BCHELMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL339813 | 0.83 | LMNA (0.82) | BCHELMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL933579 | 0.83 | APP (0.62) | BCHEMAOBMAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101580460-A | Synthesis method of 3, 4-dihydroxy phenylethanol | TAIZHOU ZHIQING CHEMICAL CO LT (CN) | 2009-11-18 | — | — | CN | claimed |
| WO-2025244832-A1 | NOVEL AMINOGUANIDINE DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | KONG'S PHARMACEUTICAL CO. (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-4387617-A1 | ACID CERAMIDASE INHIBITORS AND USES THEREOF | The Regents of the University of California (US) | 2024-06-26 | — | — | EP | disclosed |
| US-11802135-B2 | Lysophosphatidic acid derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-31 | — | — | US | disclosed |
| US-11802135-B2 | Lysophosphatidic acid derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-31 | — | — | US | disclosed |
| US-11802135-B2 | Lysophosphatidic acid derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-31 | — | — | US | disclosed |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
| WO-2023023156-A1 | ACID CERAMIDASE INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-02-23 | — | — | WO | disclosed |
| CN-1252795-A | 4, 1-benzoxazepine *, their analogs and their use as somatostatin agonists | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2000-05-10 | — | — | CN | disclosed |
| EP-0979227-A1 | 4,1-BENZOXAZEPINES, THEIR ANALOGUES, AND THEIR USE AS SOMATOSTATIN AGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2000-02-16 | — | — | EP | disclosed |
| EP-0767794-B1 | PHOSPHINIC ACID DERIVATIVES | SCHERING CORP (US) | 2000-02-02 | — | — | EP | disclosed |
| WO-1999045927-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-09-16 | — | — | WO | disclosed |
| WO-1998047882-A1 | 4,1-BENZOXAZEPINES, THEIR ANALOGUES, AND THEIR USE AS SOMATOSTATIN AGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-29 | — | — | WO | disclosed |
| US-4738972-A | Hypoglycemic thiazolidinediones | PFIZER INC. (US) | 1988-04-19 | — | — | US | disclosed |
| EP-0113964-B1 | 4-AMINOALKYL-2(3H)-INDOLONES | SMITHKLINE BECKMAN CORPORATION (US) | 1986-10-22 | — | — | EP | disclosed |
| US-4588740-A | Pharmaceutical methods using 4-aminoalkyl-2(3H)-indolones | SMITHKLINE BECKMAN CORPORATION (US) | 1986-05-13 | — | — | US | disclosed |
| EP-0113964-A1 | 4-Aminoalkyl-2(3H)-indolones | SMITHKLINE BECKMAN CORPORATION (US) | 1984-07-25 | — | — | EP | disclosed |
| US-4452808-A | HYPOTENSIVE AGENTS | SMITHKLINE BECKMAN CORPORATION (US) | 1984-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802135-B2 | Lysophosphatidic acid derivative | LPAR4, LPAR2, LPAR1 | BCHE 4294/4885LMNA 1148/4885CYP1A2 4026/4885 |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | LPAR4, LPAR2, LPAR1 | BCHE 4355/4885LMNA 1415/4885CYP1A2 4252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.